The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Open accessAbstract
Background Chimeric antigen receptor (CAR) modified T cells targeting CD19 have shown activity in case series of patients with acute and chronic lymphocytic leukaemia and B-cell lymphomas, but feasibility, toxicity, and response rates of consecutively enrolled patients treated with a consistent regimen and assessed on an intention-to-treat basis have not been reported. We aimed to define feasibility, toxicity, maximum tolerated dose, response rate, and biological correlates of response in children and young adults with refractory B-cell malignancies treated with CD19-CAR T cells. Methods This phase 1, dose-escalation trial consecutively enrolled children and young adults (aged 1-30 years) with relapsed or refractory acute lymphoblastic leukaemia or non-Hodgkin lymphoma. Autologous T cells were engineered via an 11-day manufacturing process to express a CD19-CAR incorporating an anti-CD19 single-chain variable fragment plus TCR zeta and CD28 signalling domains. All patients received fludarabine and cyclophosphamide before a single infusion of CD19-CAR T cells. Using a standard 3 + 3 design to establish the maximum tolerated dose, patients received either 1 × 10(6) CAR-transduced T cells per kg (dose 1), 3 × 10(6) CAR-transduced T cells per kg (dose 2), or the entire CAR T-cell product if sufficient numbers of cells to meet the assigned dose were not generated. After the dose-escalation phase, an expansion cohort was treated at the maximum tolerated dose. The trial is registered with ClinicalTrials.gov, number NCT01593696. Findings Between July 2, 2012, and June 20, 2014, 21 patients (including eight who had previously undergone allogeneic haematopoietic stem-cell transplantation) were enrolled and infused with CD19-CAR T cells. 19 received the prescribed dose of CD19-CAR T cells, whereas the assigned dose concentration could not be generated for two patients (90% feasible). All patients enrolled were assessed for response. The maximum tolerated dose was defined as 1 × 10(6) CD19-CAR T cells per kg. All toxicities were fully reversible, with the most severe being grade 4 cytokine release syndrome that occurred in three (14%) of 21 patients (95% CI 3·0-36·3). The most common non-haematological grade 3 adverse events were fever (nine [43%] of 21 patients), hypokalaemia (nine [43%] of 21 patients), fever and neutropenia (eight [38%] of 21 patients), and cytokine release syndrome (three [14%) of 21 patients). Interpretation CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukaemia. All toxicities were reversible and prolonged B-cell aplasia did not occur. Funding National Institutes of Health Intramural funds and St Baldrick's Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All approved CAR T-cell products are second-generation CARs that incorporate CD28 or CD137 (4-1BB) co-stimulatory signals, which are essential for eliciting effector and memory cell expansion and persistence and a clinically relevant immune response (9-15).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Further, most clinical protocols, and all the commercially approved therapies, have relied on viral vectors to deliver CAR transgenes into T cells (9-14,24-26).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“First, most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing (9-18,21,22).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 4,694
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Self-citationMorgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564
Self-citationEfficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Cited by
Sorted by citations
Items 901–1,000 of 1,006
Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer
Yan, W., Hu, H., & Tang, B. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s203550 · Cited by 51
MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells
Mao, Y., Fan, W., Hu, H., Zhang, L., Michel, J., Wu, Y., Wang, J., Jia, L., Tang, X., Xu, L., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0793-7 · Cited by 51
Self-citationZhang, Y., Chen, H., Song, Y., Tan, X., Zhao, Y., Liu, X., Li, Z., Yang, F., Jiang, M., Gao, Z., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16339 · Cited by 53
Yang, M., Wang, L., Ni, M., Neuber, B., Wang, S., Gong, W., Sauer, T., Sellner, L., Schubert, M., Hückelhoven‐Krauss, A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.608167 · Cited by 52
Direct control of CAR T cells through small molecule-regulated antibodies
Park, S., Pascua, E., Lindquist, K. C., Kimberlin, C. R., Deng, X., Mak, Y. S. L., Melton, Z., Johnson, T., Lin, R., Boldajipour, B. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20671-6 · Cited by 54
Hong, R., Hu, Y., & Huang, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627764 · Cited by 52
Vector engineering, strategies and targets in cancer gene therapy
Singh, V., Khan, N., & Jayandharan, G. R. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00331-7 · Cited by 55
CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain
Li, T., Zhao, L., Zhang, Y., Xiao, Y., Wang, D., Huang, L., Ma, L., Chen, L., Liu, S., Long, X., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01306 · Cited by 50
Qin, D., Li, D., Zhang, B., Chen, Y., Liao, X., Li, X., Alexander, P. B., Wang, Y., & Li, Q.-J. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1806009 · Cited by 49
Myers, R. M., Shah, N. N., & Pulsipher, M. A. (2022) · Blood · doi:10.1182/blood.2022016937 · Cited by 51
Self-citationCD19 CAR Therapy for Acute Lymphoblastic Leukemia
Sadelain, M., Brentjens, R. J., Rivière, I., & Park, J. H. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e360 · Cited by 50
Immunometabolism: A new target for improving cancer immunotherapy
Guo, C., Chen, S., Liu, W., Ma, Y., Li, J., Fisher, P. B., Fang, X., & Wang, X. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.004 · Cited by 56
Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications.
Mohseni, M. M., Uludağ, H., & Brandwein, J. M. (2018) · Europe PMC (PubMed Central) · Cited by 49
Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells
Alhabbab, R. Y. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00312 · Cited by 51
Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting
Sutherland, A. R., Owens, M. N., & Geyer, C. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197222 · Cited by 52
Cobb, D. A., de Rossi, J., Liu, L., An, E., & Lee, D. W. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003816 · Cited by 51
Self-citationO’Neal, J., Ritchey, J., Cooper, M. L., Niswonger, J., González, L. S., Street, E., Rettig, M. P., Gladney, S., Gehrs, L., Abboud, R., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01559-4 · Cited by 50
CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy
Mullanfiroze, K., Lazareva, A., Chu, J., Williams, L., Burridge, S., Silva, J., Chiesa, R., Rao, K., Lucchini, G., Ghorashian, S., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007572 · Cited by 49
Li, M., Jiang, P., Wei, S., Wang, J., & Li, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113312 · Cited by 52
García-Calderón, C. B., Sierro-Martínez, B., García‐Guerrero, E., Sanoja-Flores, L., Muñoz-García, R., Ruiz-Maldonado, V., Jiménez‐León, M. R., Delgado‐Serrano, J., Molinos-Quintana, Á., Guijarro-Albaladejo, B., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1152498 · Cited by 51
Nano/genetically engineered cells for immunotherapy
Shen, J., Zhou, Y., & Yin, L. (2024) · BMEMat · doi:10.1002/bmm2.12112 · Cited by 50
Magnani, C. F., Turazzi, N., Benedicenti, F., Calabria, A., Tenderini, E., Tettamanti, S., Attianese, G. M. P. G., Cooper, L. J. N., Aiuti, A., Montini, E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9955 · Cited by 49
Mei, H., Jiang, H., Wu, Y., Guo, T., Xia, L., Jin, R., & Hu, Y. (2017) · British Journal of Haematology · doi:10.1111/bjh.14680 · Cited by 51
Lonez, C., Verma, B. K., Hendlisz, A., Aftimos, P., Awada, A., Neste, E. V. D., Catala, G., Machiels, J., Piette, F., Brayer, J., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-017075 · Cited by 45
Chapelin, F., Gao, S., Okada, H., Weber, T. G., Messer, K. S., & Ahrens, E. T. (2017) · Scientific Reports · doi:10.1038/s41598-017-17669-4 · Cited by 50
Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules
Jin, J., Gkitsas-Long, N., Fellowes, V. S., Ren, J., Feldman, S. A., Hinrichs, C. S., Stroncek, D. F., & Highfill, S. L. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1384-z · Cited by 47
Self-citationHu, Y., Wang, J., Wei, G., Yu, J., Luo, Y., Shi, J., Wu, W., Zhao, K., Xiao, L., Zhang, Y., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0403-2 · Cited by 49
Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients
Itzhaki, O., Jacoby, E., Nissani, A., Levi, M., Nagler, A., Kubi, A., Brezinger, K., Brayer, H., Zeltzer, L., Rozenbaum, M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000148 · Cited by 54
Immunotherapy for Medulloblastoma: Current Perspectives
Kabir, T., Kunos, C. A., Villano, J. L., & Chauhan, A. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s198162 · Cited by 51
Ravich, J. W., Huang, S., Zhou, Y., Brown, P. A., Pui, C., Inaba, H., Cheng, C., Gottschalk, S. M., Triplett, B. M., Bonifant, C. L., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.11.019 · Cited by 49
Wang, L., Hong, R., Zhou, L., Ni, F., Zhang, M., Zhao, H., Wu, W., Wang, Y., Ding, S., Chang, A. H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.702644 · Cited by 49
RCMNet: A deep learning model assists CAR-T therapy for leukemia
Zhang, R., Han, X., Lei, Z., Jiang, C., Gul, I., Hu, Q., Zhai, S., Liu, H., Lian, L., Liu, Y., et al. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.106084 · Cited by 51
Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia
Wu, G., Guo, S., Luo, Q., Wang, X., Deng, W., Ouyang, G., Pu, J. J., Lei, W., & Qian, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1093750 · Cited by 51
Cadiñanos-Garai, A., Flugel, C., Cheung, A., Jiang, E., Vaissié, A., & Abou‐El‐Enein, M. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.006 · Cited by 52
A novel Epstein–Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy
Cho, H.-I., Kim, U.-H., Shin, A.-R., Won, J.-N., Lee, H.-J., Sohn, H., & Kim, T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.475 · Cited by 48
New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment
Cheung, L. C., Tickner, J. C., Hughes, A. M., Skut, P., Howlett, M., Foley, B. A., Oommen, J., Wells, J. E., He, B., Singh, S., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0144-7 · Cited by 48
TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells
Li, D., Hu, Y., Jin, Z., Zhai, Y., Tan, Y., Sun, Y., Zhu, S., Zhao, C., Chen, B., Zhu, J., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0212-z · Cited by 48
Kim, H., Griffith, T. S., & Panyam, J. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.254953 · Cited by 49
The NKG2D axis: an emerging target in cancer immunotherapy
Lazarova, M., & Steinle, A. (2019) · Expert opinion on therapeutic targets · doi:10.1080/14728222.2019.1580693 · Cited by 40
Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives
Lee, Y.-H., & Kim, C. H. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01136-x · Cited by 50
T cell immunotherapy enhanced by designer biomaterials
Dunn, Z. S., Mac, J., & Wang, P. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119265 · Cited by 48
Marofi, F., Rahman, H. S., Achmad, M. H., Sergeevna, K. N., Suksatan, W., Abdelbasset, W. K., Mikhailova, M. V., Shomali, N., Yazdanifar, M., Hassanzadeh, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.681984 · Cited by 48
RetractedZhang, M., Zhou, L., Zhao, H., Zhang, Y., Wei, G., Hong, R., Wu, W., Xu, H., Wang, L., Ni, F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2031 · Cited by 48
Wayne, A. S., Huynh, V., Hijiya, N., Rouce, R. H., Brown, P. A., Krueger, J., Kitko, C. L., Ziga, E. D., Hermiston, M. L., Richards, M. K., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.280678 · Cited by 48
Self-citationTRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers
Nichakawade, T. D., Ge, J., Mog, B. J., Lee, B. S., Pearlman, A. H., Hwang, M. S., DiNapoli, S. R., Wyhs, N., Marcou, N., Glavaris, S. A., et al. (2024) · Nature · doi:10.1038/s41586-024-07233-2 · Cited by 48
Ramachandran, M., Dimberg, A., & Essand, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.02.010 · Cited by 49
The development of CAR design for tumor CAR-T cell therapy
Xu, D., Jin, G., Chai, D., Zhou, X., Gu, W., Chong, Y., Song, J., & Zheng, J. (2018) · Oncotarget · doi:10.18632/oncotarget.24179 · Cited by 47
Transcriptome and Regulatory Network Analyses of CD19-CAR-T Immunotherapy for B-ALL
Zhang, Q., Hu, H., Chen, S., Liu, C., Hu, F., Yu, J., Wu, Y., & Guo, A. (2019) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2018.12.008 · Cited by 47
Zhao, Y. Q., Liu, Z., Wang, X., Wu, H., Zhang, J., Yang, J., Zhang, F., Liu, L., Long, J., Lu, P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0916 · Cited by 47
Aldoss, I. T., & Forman, S. J. (2020) · Blood · doi:10.1182/blood.2019002132 · Cited by 48
CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm
Bôle‐Richard, E., Fredon, M., Biichlé, S., Anna, F., Certoux, J.-M., Renosi, F., Tsé, F., Molimard, C., Valmary‐Degano, S., Jenvrin, A., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0777-1 · Cited by 52
Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells
Dayagi, T. W., Sherman, G., Bielorai, B., Adam, E., Besser, M. J., Shimoni, A., Nagler, A., Toren, A., Jacoby, E., & Avigdor, A. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1881506 · Cited by 47
Wendel, P., Reindl, L. M., Bexte, T., Künnemeyer, L., Särchen, V., Albinger, N., Mackensen, A., Rettinger, E., Bopp, T., & Ullrich, E. (2021) · Cancers · doi:10.3390/cancers13061481 · Cited by 48
Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies.
Jung, I.-Y., & Lee, J. (2018) · Europe PMC (PubMed Central) · doi:10.14348/molcells.2018.0242 · Cited by 49
Brudno, J. N., Natrakul, D. A., Lam, N., Dulau‐Florea, A., Yuan, C. M., & Kochenderfer, J. N. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2056172 · Cited by 46
Self-citationAcute Lymphoblastic Leukemia Immunotherapy Treatment: Now, Next, and Beyond
Aureli, A., Marziani, B., Venditti, A., Sconocchia, T., & Sconocchia, G. (2023) · Cancers · doi:10.3390/cancers15133346 · Cited by 54
CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy
Guo, S., Lei, W., Jin, X., Liu, H., Wang, J. Q., Deng, W., & Qian, W. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012202 · Cited by 46
Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy
Lin, M.-Y., Nam, E., Shih, R. M., Shafer, A., Bouren, A., Ceja, M. A., Harris, C. M., Khericha, M., Vo, K., Kim, M., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20221988 · Cited by 48
Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
Canedo, G. D. O., Roddie, C., & Amrolia, P. J. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013586 · Cited by 47
Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy
Huang, Z., Lai, Y.-S., Li, Y., Blum, R. H., & Kaufman, D. S. (2017) · Stem Cells · doi:10.1002/stem.2754 · Cited by 48
CAR T-cell bioengineering: Single variable domain of heavy chain antibody targeted CARs
Rahbarizadeh, F., Ahmadvand, D., & Moghimi, S. M. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.04.006 · Cited by 51
Chimeric antigen receptor–T cells with cytokine neutralizing capacity
Tan, A. H. J., Vinanica, N., & Campana, D. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001287 · Cited by 45
Pabst, T., Joncourt, R., Shumilov, E., Heini, A. D., Wiedemann, G., Legros, M., Seipel, K., Schild, C., Jalowiec, K. A., Taleghani, B. M., et al. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.07.003 · Cited by 50
Wang, X., Huynh, C., Urak, R. Z., Weng, L., Walter, M., Lim, L., Vyas, V., Chang, W.-C., Aguilar, B., Brito, A., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0236 · Cited by 46
Marofi, F., Rahman, H. S., Thangavelu, L. P., Dorofeev, A. E., Bayas-Morejón, F., Shirafkan, N., Shomali, N., Chartrand, M. S., Jarahian, M., Vahedi, G., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02251-7 · Cited by 47
Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival
Julamanee, J., Terakura, S., Umemura, K., Adachi, Y., Miyao, K., Okuno, S., Takagi, E., Sakai, T., Koyama, D., Goto, T., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.038 · Cited by 47
Mechanisms of resistance to CAR T cell therapies
Singh, N., Orlando, E. J., Xu, J., Xu, J., Binder, Z. A., Collins, M. A., O’Rourke, D. M., & Melenhorst, J. J. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.002 · Cited by 48
van Hees, M., Slott, S., Hansen, A. H., Kim, H. S., Ji, H. P., & Astakhova, K. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.003 · Cited by 47
Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
Moon, D., Tae, N., Park, Y., Lee, S., & Kim, D. H. (2022) · Immune Network · doi:10.4110/in.2022.22.e4 · Cited by 48
Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer
Kandra, P., Nandigama, R., Eul, B. G., Huber, M., Kobold, S., Seeger, W., Grimminger, F., & Savai, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903562 · Cited by 50
Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia
Zhang, C., He, J., Liu, L., Wang, J., Wang, S., Liu, L., Ge, J., Gao, L., Gao, L., Kong, P., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00688-4 · Cited by 45
Current status of immunotherapy for non-small cell lung cancer
Yang, T., Xiong, Y., Zeng, Y., Wang, Y., Zeng, J., Liu, J., Xu, S., & Li, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.989461 · Cited by 45
Fischer‐Riepe, L., Kailayangiri, S., Zimmermann, K., Pfeifer, R., Aigner, M., Altvater, B., Kretschmann, S., Völkl, S., Hartley, J., Dreger, C., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3157 · Cited by 45
Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects
Guo, Y., Wang, Y., & Han, W. (2016) · Journal of Immunology Research · doi:10.1155/2016/3850839 · Cited by 45
Oluwole, O. O., & Davila, M. L. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.5bt1115-524r · Cited by 46
New targeted therapies for relapsed pediatric acute lymphoblastic leukemia
Pierro, J., Hogan, L. E., Bhatla, T., & Carroll, W. L. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1347507 · Cited by 47
Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
Tomuleasa, C., Fuji, S., Berce, C., Onaciu, A., Chira, S., Petrushev, B., Micu, W.-T., Moisoiu, V., Osan, C., Constantinescu, C. S., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00239 · Cited by 46
Effects of cryopreservation on chimeric antigen receptor T cell functions
Xu, H., Cao, W., Huang, L., Xiao, M., Cao, Y., Zhao, L., Wang, N., & Zhou, J. (2018) · Cryobiology · doi:10.1016/j.cryobiol.2018.06.007 · Cited by 49
Computational Model of Chimeric Antigen Receptors Explains Site-Specific Phosphorylation Kinetics
Rohrs, J. A., Zheng, D., Graham, N. A., Wang, P., & Finley, S. D. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2018.08.018 · Cited by 42
Cao, J., Wang, H., Gao, W., You, J., Wu, L.-H., & Wang, Z.-X. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.01.015 · Cited by 45
VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma
Englisch, A., Altvater, B., Kailayangiri, S., Hartmann, W., & Rössig, C. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28313 · Cited by 48
Rubinstein, J. D., Krupski, C., Nelson, A. S., O'Brien, M. M., Davies, S. M., & Phillips, C. L. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.07.036 · Cited by 47
Immunotherapies for pediatric cancer: current landscape and future perspectives
Hutzen, B., Paudel, S. N., Naeimi Kararoudi, M., Cassady, K. A., Lee, D. A., & Cripe, T. P. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09819-z · Cited by 44
Self-citationT Cell Reprogramming Against Cancer
Katz, S. G., & Rabinovich, P. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-0716-0203-4_1 · Cited by 45
CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy
Elmas, E., Saljoughian, N., Pereira, M. D. S. F., Tullius, B. P., Sorathia, K., Nakkula, R. J., Lee, D. A., & Kararoudi, M. N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.834002 · Cited by 47
Self-citationMansour, A. G., Teng, K., Li, Z., Zhu, Z. G., Chen, H., Tian, L., Ali, A., Zhang, J., Lu, T., Ma, S., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022007405 · Cited by 44
Merker, M., Pfirrmann, V., Oelsner, S., Fulda, S., Klingebiel, T. E., Wels, W. S., Bader, P., & Rettinger, E. (2017) · Oncotarget · doi:10.18632/oncotarget.19821 · Cited by 42
Mapping and targeting of the leukemic microenvironment
Witkowski, M. T., Kousteni, S., & Aifantis, I. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190589 · Cited by 47
Cutting to the Front of the Line: Immunotherapy for Childhood Acute Lymphoblastic Leukemia
McNeer, J. L., Rau, R. E., Gupta, S., Maude, S. L., & O'Brien, M. M. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_278171 · Cited by 44
Noninvasive Imaging of Cancer Immunotherapy
Abousaway, O., Rakhshandehroo, T., den Abbeele, A. D. V., Kircher, M. F., & Rashidian, M. (2020) · Nanotheranostics · doi:10.7150/ntno.50860 · Cited by 44
Reagan, P. M., & Neelapu, S. S. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01616 · Cited by 44
Moghanloo, E., Mollanoori, H., Talebi, M., Pashangzadeh, S., Faraji, F., Hadjilooei, F., & Mahmoodzadeh, H. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101070 · Cited by 45
Kalinin, R. S., Ukrainskaya, V. M., Chumakov, S. P., Moysenovich, A. M., Tereshchuk, V. M., Volkov, D. V., Pershin, D., Maksimov, E. G., Zhang, H., Maschan, M. A., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.745286 · Cited by 44
Self-citationElectrolyte and Acid-Base Disorders Associated with Cancer Immunotherapy
Uppal, N. N., Workeneh, B. T., Rondon‐Berrios, H., & Jhaveri, K. D. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14671121 · Cited by 44
Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment
Cramer, S. D., Aplan, P. D., & Durum, S. K. (2016) · Blood · doi:10.1182/blood-2016-03-679209 · Cited by 43
Li, W., Zhu, X., Xu, Y., Chen, J., Zhang, H., Yang, Z., Qi, Y., Hong, J., Li, Y., Wang, G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1052717 · Cited by 49
Self-citationCAR T ‐cells merge into the fast lane of cancer care
Frey, N. V., & Porter, D. (2015) · American Journal of Hematology · doi:10.1002/ajh.24238 · Cited by 43
Adoptive Cell Therapy: Past, Present and Future
Cohen, J. E., Merims, S., Frank, S. J., Engelstein, R., Peretz, T., & Lotem, M. (2017) · Immunotherapy · doi:10.2217/imt-2016-0112 · Cited by 45
Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It
Short, N. J., & Jabbour, E. J. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0565-x · Cited by 43
Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again
Bucktrout, S. L., Bluestone, J. A., & Ramsdell, F. (2018) · Genome Medicine · doi:10.1186/s13073-018-0588-4 · Cited by 47
Metadata
- Authors
- Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., Steinberg, S. M., Stroncek, D., Tschernia, N., Yuan, C., Zhang, H., Zhang, L., Rosenberg, S. A., Wayne, A. S., & Mackall, C. L.
- Affiliations
- National Institutes of Health (US)
- National Cancer Institute (US)
- University of Nevada, Reno (US)
- University of Southern California (US)
- Corresponding author
- Mackall, Crystal L
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 385
- Issue
- 9967
- Pages
- 517-528
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC7065359
- OpenAlex
- W2129702476
- Cited by
- 2,898
- References
- 37
- Citations by year
- 2026: 86 · 2025: 154 · 2024: 175 · 2023: 217 · 2022: 275 · 2021: 311 · 2020: 350 · 2019: 317 · 2018: 315 · 2017: 314 · 2016: 232 · 2015: 134
- FWCI
- 103.68
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- St. Baldrick's Foundation
- Entertainment Industry Foundation
- National Institutes of Health
- National Cancer Institute (Z01BC011072, Z01BC010566, Z01BC011024)
- National Institute of Allergy and Infectious Diseases
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CD19 chimeric antigen receptor, CAR T-cell therapy, acute lymphoblastic leukemia, non-Hodgkin lymphoma, relapsed or refractory B-cell malignancies, maximum tolerated dose, cytokine release syndrome, neurotoxicity, non-relapse mortality, fludarabine and cyclophosphamide conditioning
- MeSH terms
- Adolescent, Adult, Child, Child, Preschool, Chimera, Feasibility Studies, Female, Humans, Infant, Lymphoma, Non-Hodgkin, Male, Receptors, Antigen, T-Cell, T-Lymphocytes, Cohort Studies, Treatment Outcome, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
